Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by chronic inflammatory processes that activate the innate immune system and the production of antibodies that destroy host tissues. These inflammatory processes can be caused by genetic or environmental factors or infections.

The global Autoimmune Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Autoimmune Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Autoimmune Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Autoimmune Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Autoimmune Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Eli Lilly
GSK
AbbVie
Johnson & Johnson
Biogen
Amgen
Pfizer
Roche
Baxter

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Rheumatoid Arthritis (RA)
Multiple Sclerosis (MS)
Psoriasis
Inflammatory Bowel Disease (IBD)
Ankylosing Spondylitis (AS)
Systemic Lupus Erythematosus (SLE)

Segment by Application
Hospitals
Homecare Settings
Specialty Clinics